RxDoctor Payments Data

Lindsay Tavares, MD

Ophthalmology · Tucson, AZNPI 1104056944

Payments from drug & device makers

$1,368in general payments, 2019–2025

Across 64 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$332
  • Bausch & Lomb Americas Inc.$185
  • Dompe US, Inc.$161
  • AbbVie$109
  • Alcon$96
  • Harrow Eye, LLC$88
  • plus $396 from 10 others

What the payments were for

  • Food & beverage$1,28894%
  • Education$806%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,368 in reported general payments places this provider in the 45th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$194,123
Medicare patients
593
Services billed
1,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine122$122,699
RocklatanNetarsudil Mesylat/Latanoprost196$81,088
XiidraLifitegrast40$55,317
TyrvayaVarenicline Tartrate40$24,723
MieboPerfluorohexyloctane/Pf23$18,440
Cyclosporine24$15,480
LumiganBimatoprost27$13,256
VyzultaLatanoprostene Bunod29$8,292
RhopressaNetarsudil Mesylate14$6,971
Latanoprost501$5,015
SimbrinzaBrinzolamide/Brimonidine Tart17$4,963
Travoprost35$4,080
Prednisolone Acetate84$3,917
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat174$2,456
Timolol Maleate198$2,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$109$135,955149 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$61$88,059210 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$185$82,04992 claims
Oyster Point Pharma, Inc.Tyrvaya$82$24,72340 claims
AlconSimbrinza$96$4,96317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →